Following promising trial results, retatrutide, a new peptide option for treating adult-onset metabolic disorder, has received conditional approval from Great Britain's Medicines and Healthcare Agency (MHRA ). Initial availability is currently anticipated via dedicated obesity centres and certain National Health Service providers in late year , wit